Phathom Pharmaceuticals 已提前完成其针对嗜酸性粒细胞性食管炎(EoE)的二期临床试验 Phalcon-Eoe-201 的患者招募工作。该试验旨在评估其药物 Voquezna®(Vonoprazan)的疗效与安全性。这一进展标志着公司在推进该创新疗法的临床开发道路上迈出了关键一步。
Phathom Pharmaceuticals 已提前完成其针对嗜酸性粒细胞性食管炎(EoE)的二期临床试验 Phalcon-Eoe-201 的患者招募工作。该试验旨在评估其药物 Voquezna®(Vonoprazan)的疗效与安全性。这一进展标志着公司在推进该创新疗法的临床开发道路上迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.